位置:成果数据库 > 期刊 > 期刊详情页
替比夫定对慢性乙型肝炎患者外周血CD4+ CD25+ CD127(low) T和CD8+ CD25+ T细胞频率的影响及临床意义
  • ISSN号:1000-8861
  • 期刊名称:《免疫学杂志》
  • 时间:0
  • 分类:R392.12[医药卫生—免疫学;医药卫生—基础医学]
  • 作者机构:[1]第三军医大学全军免疫学研究所,重庆400038, [2]西南医院感染科, [3]学员旅7队
  • 相关基金:国家自然基金资助项目(30872352)
中文摘要:

目的探讨核苷类药物替比夫定对慢性乙肝患者(CHB)外周血中CD4+CD25+CD127lowT细胞和CD8+CD25+T细胞比例的影响,并结合临床指标分析其临床意义。方法替比夫定抗病毒治疗22例CHB患者,在治疗前及治疗后3,6个月时,分别以流式细胞仪检测外周血中CD4+CD25+CD127lowT细胞和CD8+CD25+T细胞比例,实时荧光定量RT-PCR检测Foxp3 mRNA的表达水平,荧光定量PCR检测血清HBV DNA水平,酶联免疫吸附法检测HBV标志物,全自动生化分析仪检测ALT水平。结果 CHB患者外周血中CD4+CD25+CD127lowT细胞和CD8+CD25+T细胞比例显著高于对照组。替比夫定治疗3个月时,这两群细胞比例显著下降,Foxp3 mRNA的表达也显著下降;HBV DNA水平降至检测水平以下的CHB患者,其CD4+CD25+CD127lowT细胞也降至正常水平。治疗3、6个月时,HBeAg阴转率分别为9.1%和18.2%,发生HBeAg血清学转换者的CD4+CD25+CD127lowT细胞和CD8+CD25+T细胞比例均降至正常水平。结论替比夫定能快速有效抑制CHB患者的病毒复制,同时CD4+CD25+CD127lowT细胞和CD8+CD25+T细胞比例显著下调,可能降低了Treg对HBV特异性T淋巴细胞的抑制作用,改善了机体的免疫应答。

英文摘要:

This study aimed to investigate the effects of telbivudine on peripheral blood CD4+ CD25+ CD127 low T cells and CD8+ CD25+ T cells and its significance in patients with chronic hepatitis B.Twenty-two HBeAg positive chronic hepatitis B patients were recruited and received telbivudine treatment.Before and during the 3 or 6 months of treatment,the proportion of peripheral blood CD4+ CD25+ CD127 low T cells and CD8+ CD25+ T cells was detected by flow cytometry;the levels of HBV DNA in the serum were assayed by real-time PCR;the levels of Foxp3 mRNA were measured by real-time RT PCR;markers of hepatitis B virus infection were detected by ELISA assay and levels of alanine aminotransferase in the serum were measured.The proportion of peripheral blood CD4+ CD25+ CD127 low T cells and CD8+ CD25+ T cells in patients with CHB was significantly higher than that in healthy controls and decreased after 3 or 6 months of telbivudine treatment to a level comparable to that of the healthy controls.The levels of HBV DNA in patients,whose proportion of peripheral blood CD4+ CD25+ CD127 low T cells was also decreased to a level comparable to that of the healthy control,were undetectable.Three and six months of telbivudine treatments resulted in HBeAg negativity in 2 patients(9.1%) and 4 patients(18.2%),respectively.All these results indicate that telbivudine treatment not only reduce serum HBV DNA levels rapidly and profoundly,but also indirectly affect immune system by downregulating the proportion of peripheral blood CD4+ CD25+ CD127 low T cells and CD8+ CD25+ T cells markedly,which is probably beneficial to restore antivirus immune response.

同期刊论文项目
同项目期刊论文
期刊信息
  • 《免疫学杂志》
  • 中国科技核心期刊
  • 主管单位:第三军医大学
  • 主办单位:第三军医大学 中国免疫学会
  • 主编:吴玉章
  • 地址:重庆市沙坪坝高滩岩
  • 邮编:400038
  • 邮箱:richard@mail.tmmu.com.cn
  • 电话:023-68752237
  • 国际标准刊号:ISSN:1000-8861
  • 国内统一刊号:ISSN:51-1332/R
  • 邮发代号:78-32
  • 获奖情况:
  • 中国科协优秀科技期刊三等奖,全军优秀医学期刊奖,重庆市优秀期刊一等奖
  • 国内外数据库收录:
  • 美国化学文摘(网络版),波兰哥白尼索引,美国剑桥科学文摘,日本日本科学技术振兴机构数据库,中国中国科技核心期刊,中国北大核心期刊(2004版),中国北大核心期刊(2008版),中国北大核心期刊(2011版),中国北大核心期刊(2014版),中国北大核心期刊(2000版)
  • 被引量:13273